Despite substantial progress in increasing the survival rates for most human cancers, PDAC remains highly lethal [1] [2] [3] and is projected to be the second leading cause of cancer deaths in the western world by 2020 (ref. 4). Primary PDACs have been shown to contain distinct subclonal populations. However, these subclones share identical driver mutations and the genetics of metastases largely reflects that of the primary tumor 1 . Furthermore, subclones are defined genetically by their unique progressor mutations, the vast majority if not all of which are thought to be passenger events 1 . This raises questions as to what mechanisms might drive progression and metastasis during the natural history of disease evolution.
sequence-verified clonal tumor sections from five patients). For each patient, sections were taken from different regions of the primary tumor that were occupied by distinct clones, including from the common ancestor that founded the neoplasm (founder clone) and the subclone descendants that seeded metastasis. These were further matched to the corresponding metastases from the same patients, each of which had driver mutations identical to those of the primary tumor (Supplementary Table 1 ). We performed immunostaining against dimethylated (H3K9me2) and trimethylated (H3K9me3) H3K9 across these sections to detect global changes from heterochromatin domains (including LOCKs 5, 12 ) that might be selectable targets during subclonal evolution. This revealed uniform, diffusely positive (>80%) staining for H3K9me2 and H3K9me3 in PDAC nuclei across all tumor sections from patients with regional (peritoneal) metastatic disease ( Fig. 1a and Supplementary Fig. 1a) . In contrast, samples from patients who presented with widespread distant metastases (liver and lung) displayed progressive loss of H3K9me2 and H3K9me3 during subclonal evolution. This manifested as heterogeneous (positive and negative) staining in primary tumor subclones, with either diffusely negative staining (<20%) or retention of heterogeneous staining in the metastases ( Fig. 1b and Supplementary Fig. 1b ). As in the individual patients above, we observed similar results for matched primary tumor subclones that seeded either peritoneal or distant metastases within the same patient ( Supplementary Fig. 1c) . Thus, global heterochromatin modifications remained stable during peritoneal spread. In contrast, global reprogramming initiated in primary tumor subclones that seeded distant metastases, and these changes were inherited or even accentuated in the metastases themselves.
To expand our analysis and test the generality of our findings, we employed 12 low-passage cell lines collected from eight patients by rapid autopsy (Supplementary Table 1 ), including a subset that corresponded to the formalin-fixed patient tissues (from Supplementary  Fig. 1c ). Cell lines were isolated from nine distant metastases, a peritoneal metastasis with matched liver and lung metastases from the same patient, and two primary tumor subclones matched to a lung metastasis from another patient. Notably, six of the cell lines derived from distant metastases were previously subjected to whole-exome sequencing 9 , and mutations were also present in the corresponding patient tissues 1 . PDAC cell lines derived from other sources of regional disease were also included: malignant ascites fluid from two patients (AsPC1 (ref. 13 ) and HPAFII 14 ) and a primary tumor from a long-term survivor without distant metastases (Capan2 (ref. 15) ).
We examined whether the global changes in chromatin detected in patient tissues were maintained in cell lines, which could reflect a reprogrammed epigenomic state. We began by performing immunoblotting for eight histone modifications with well-understood functions 16 . Comparison of regional PDAC samples showed minimal or non-recurrent global changes across all histone modifications tested ( Supplementary Fig. 1d ), similar to the evolution of peritoneal disease observed in patient tissues. In contrast, distant metastases displayed striking reprogramming of specific histone methylation and acetylation marks (Fig. 1c,d and Supplementary Fig. 1e ), including between matched peritoneal and distant metastatic subclones (Fig. 1c) that corresponded to the patient tissues presented in Supplementary  Figure 1c . This manifested as recurrent reductions in H3K9me2, H3K9me3, and trimethylation of histone H4 at lysine 20 (H4K20me3) that were coupled to increased acetylation of H3K9 (H3K9ac), H3 lysine 27 (H3K27ac), and H4 lysine 16 (H4K16ac) in distant metastases (Fig. 1d) . H3K9 methylation is enriched in large heterochromatin domains, including LOCKs 5, 12, 17, 18 , and H3K27ac marks active gene regulatory elements 16 . Reprogramming appeared specific, as we observed no consistent or recurrent changes in trimethylation of histone H3 at lysine 27 (H3K27me3) or lysine 36 (H3K36me3) across samples ( Fig. 1d) and the reprogrammed modifications themselves were not dependent on proliferation rates or PDAC chemotherapy ( Supplementary Fig. 2 and Supplementary Table 1) . Finally, immunoblots on cell lines derived from matched primary tumor and distant metastatic subclones collected from a patient who presented with widespread distant metastases 1, 19 also showed reductions in H3K9me3 and H4K20me3 between primary tumor subclones that were inherited by the distant metastasis (Supplementary Fig. 1f) , further suggesting that reprogramming was initiated in primary tumor subclones. Thus, in vivo tissue and in vitro cell culture findings across the collective Fig. 1e,f) . n = 8 biological replicates; error bars, s.e.m. *P < 0.01, two-tailed t test.
30 patient samples strongly suggested that the global epigenetic state was reprogrammed during the evolution of distant metastasis.
The epigenomic landscape of PDAC subclonal evolution
We next wished to map the locations of reprogrammed chromatin modifications across the PDAC genome. To this end, we comprehensively mapped the epigenomic landscape of PDAC evolution with ChIP-seq for histone modifications with well-understood functions (heterochromatin: H3K9me2, H3K9me3, and H3K27me3; euchromatin: H3K27ac and H3K36me3). To capture the evolutionary diversity of malignant progression, ChIP-seq was performed on sequence-verified cell lines isolated from a peritoneal metastasis (A38Per) matched to a lung metastasis (A38Lg) from the same patient 1 and on two primary tumor subclones (A13Pr1 and A13Pr2) that were also matched to a lung metastasis (A13Lg) from the same patient 1, 19 . RNA-seq was performed in parallel to identify matched gene expression changes. Finally, these data sets were complemented with whole-genome bisulfite sequencing (WGBS) across these cell lines and frozen tumor tissues that corresponded to a subset of the formalin-fixed tumor sections. In all, we generated 160 data sets with 12.7 × 10 9 uniquely aligned sequencing reads, including >15.0 × 10 6 (median of 32.3 × 10 6 ) uniquely aligned reads, for each ChIP-seq experiment, as recommended by Encyclopedia of DNA Elements (ENCODE) guidelines 20 . Experiments were performed as biological replicates, with strong correlation between replicates (Supplementary Table 2) . Because of the divergence in global epigenetic state between peritoneal and distant metastatic samples, we compared the peritoneal subclone against the distant metastases and their matched primary tumor subclones. This comparison identified a striking degree of epigenomic reprogramming that was targeted to thousands of large chromatin domains. These domains included heterochromatin regions corresponding to LOCKs 5 that occupied approximately half of the genome, gene-rich euchromatin domains (ECDs) that occupied one-third of the genome, and a smaller subset of other very large LOCK domains. Domain characteristics are detailed in Supplementary Table 3 , and comprehensive statistical tests of significance are presented in Supplementary Table 4 .
We first analyzed heterochromatin domains defined by broad enrichment of H3K9me2, H3K9me3, and H3K27me3 ( Fig. 2a and Supplementary Fig. 3a) . Thousands of large (median lengths of 232-311 kb), block-like heterochromatin domains were detected in each sample (detailed in the Supplementary Note), and these domains significantly overlapped with previously reported LOCK domains (average of 76.7 ± 16.9% overlap; P < 0.01 by permutation testing). Domain calls were robust: varying threshold parameters across multiple sensitivity analyses produced nearly identical enrichments ( Supplementary Fig. 3b ) with overlapping genomic coordinates (Supplementary Table 4g ). Similar to the immunostaining and immunoblot data, we detected strong H3K9me2 enrichment across LOCKs in the peritoneal subclone, whereas the same regions displayed global reductions in H3K9me2 in the distant metastases and primary tumor precursors (average: 591 Mb/1,470 Mb; P < 2.2 × 10 −16 , χ 2 test; Fig. 2a and Supplementary Table 4a ). In contrast, high global levels of H3K27me3 were detected from these regions across all subclones (Fig. 2a) , similar to immunoblot findings. We further detected patient-specific patterns of H3K9me3 reduction from reprogrammed LOCKs that also matched the immunoblot findings ( Supplementary Fig. 4 and Supplementary Note). Finally, we detected localized, reciprocal changes in H3K27ac and H3K9me2 over promoters coupled to similar reciprocal changes in H3K36me3 and H3K27me3 over gene bodies within LOCK genes that were differentially expressed between subclones (Supplementary Fig. 5 ), suggesting that differentially expressed genes resided within hybrid LOCK subregions with gene regulatory potential that resemble euchromatin islands (LOCK-EIs 21 ).
Because LOCKs correspond to a subset of block-like regions that are DNA hypomethylated in pancreatic and other human cancers 6,7 , we next asked whether DNA methylation changes were also targeted to LOCKs during PDAC subclonal evolution. For this analysis, we performed WGBS on all of the cell lines with ChIP-seq data reported above. We also selected seven frozen tissue samples for in vivo WGBS that were matched to the formalin-fixed tissues with immunohistochemistry data presented in Figure 1a ,b. Normal pancreas was included with the frozen tissue samples as an internal control. Similar to ChIP-seq analysis for H3K9me2, these experiments identified significant reductions in LOCK-wide DNA methylation across cell lines isolated from distant metastases relative to peritoneal carcinomatosis (Fig. 2b,c and Supplementary Table 5 ). Analysis of the same LOCK regions in the frozen tissue samples also showed relatively high DNA methylation in LOCKs from patient A124 (peritoneal spread) and the founder clone from patient A125, whereas the primary tumor and distant metastatic subclone descendants displayed striking loss of DNA methylation (Fig. 2b,c and Supplementary Table 6 ). We also detected localized DNA hypomethylation at downregulated differentially expressed genes in the hybrid LOCK-EI subregions, whereas upregulated genes remained hypermethylated with sharp decreases in methylation at the 5′ ends of the genes, similar to the pattern observed for H3K9me2 (Supplementary Fig. 5 ). Thus, DNA methylation was globally and locally reprogrammed across LOCKs from primary tumor and distant metastatic subclones, similar to histone modifications. Based on the collective immunostain, immunoblot, ChIP-seq, and WGBS data (summarized in Supplementary Table 1) , we conclude that a substantial fraction of global reprogramming events were targeted to heterochromatin domains (LOCKs) during the evolution of distant metastasis.
We next analyzed reprogramming within ECDs, which were defined by enrichment for the euchromatin modifications H3K27ac and H3K36me3 with depletion of heterochromatin modifications ( Supplementary Fig. 6a ). Similar to heterochromatin, we detected thousands of large block-like ECDs in each sample (Supplementary Note), and ECD calls were also robust by sensitivity analyses (Supplementary Fig. 6b ). Globally, all subclones displayed broad H3K36me3 signal over gene bodies flanked by sharp peaks of H3K27ac and dips in DNA methylation at gene regulatory elements, consistent with actively transcribed euchromatin (Fig. 2d) . However, mapping differentially expressed genes from RNA-seq data to ECDs identified clear patterns of local reprogramming within the chromatin encoding these genes (Fig. 2e) . Genes upregulated from ECDs acquired increased levels of both H3K36me3 and H3K27ac, which could reflect a permissive chromatin state or hyperactive transcription. In contrast, downregulated genes displayed greatly reduced H3K36me3 with only modest reductions in H2K27ac, which could reflect an inactive yet poised chromatin state or direct transcriptional repression. Thus, reprogramming in ECDs was largely localized to chromatin that encoded differentially expressed genes.
Finally, we detected patient-specific reprogramming targeted to a unique subset of very large LOCK domains (median lengths of 730-1,340 kb; Supplementary Fig. 7 ). Although these regions were situated within DNA-hypomethylated blocks, similar to other LOCKs 6,7 , they differed in several other respects. As detailed in the Supplementary Note, these domains were substantially larger thanA r t i c l e s other LOCKs, they were strongly enriched for H3K9me3 (ref. 22) yet depleted of H3K9me2 and H3K27me3, and reprogramming was characterized by striking loss of H3K9me3 coupled with increased H3K9me2 and DNA methylation. Although the functional significance of these findings is uncertain, they strongly correlated with patterns of genome instability.
Reprogrammed chromatin domains specify malignant heterogeneity Subclonal evolution may generate substantial phenotypic heterogeneity within an individual patient 23 . We therefore wished to investigate in depth whether reprogrammed chromatin domains might encode heterogeneous malignant properties among PDAC subclones from the same patient. To this end, we selected matched subclones from the same patient (A38Per and A38Lg), performed Gene Ontology (GO) analyses on LOCK and ECD genes that were differentially expressed between the subclones (Supplementary Tables 7-11) , and tested whether GO results matched actual phenotypic differences with experimental assays. This approach revealed that reprogrammed LOCKs and ECDs encoded substantial malignant divergence. First, a large number of differentially expressed genes linked to oxidoreductase activity were upregulated from LOCKs in A38Lg (Supplementary Table 8 ). This subclone was accordingly highly resistant to hydrogen peroxide-mediated oxidative stress (Fig. 3a) and possessed higher oxidoreductase activity and NADPH concentration than A38Per (Supplementary Fig. 8a,b) . Second, genes encoding differentiation state (epithelial versus mesenchymal) were reciprocally expressed from A38Per and A38Lg LOCKs ( Fig. 3b and Supplementary Table 9 ). Consistent with this finding, A38Per maintained a well-differentiated (epithelial) morphology, whereas A38Lg was poorly differentiated (epithelial-mesenchymal transition (EMT)-like) across multiple culture conditions ( Supplementary  Fig. 8c) , and EMT emerged in the primary tumor subclone that seeded the A38Lg metastasis in vivo (Supplementary Fig. 8d) . Immune-related genes were also differentially expressed from reprogrammed LOCKs (Supplementary Table 9 ), which could hold implications for PDAC immunotherapy. Third, genes encoding proteins involved in DNA repair were upregulated from ECDs in A38Lg, including those crucial for maintenance of genome integrity (for example, genes in the Fanconi anemia complex; Supplementary Table 10 ). This subclone was accordingly highly resistant to PDAC chemotherapy (Fig. 3c) , and immunoblots showed hyperphosphorylation of the DNA repair target histone H2AX at Ser139 (γH2AX; Fig. 3d) . Fourth, genes involved in oncogenic signal transduction were downregulated from ECDs in A38Lg, especially genes related to KRAS-ERK signaling (Supplementary Table 11 ). Indeed, A38Lg showed loss of phosphorylated ERK (Fig. 3e) , resistance to ERK inhibition (Fig. 3f) , and minimal response to knockdown of oncogenic KRAS in 3D tumor-forming assays ( Fig. 3g and Supplementary  Fig. 8e,f) , despite possessing identical KRAS G12V mutations as A38Per 1 . Finally, mapping previously reported rearrangements from this patient 10 to chromatin domains showed that rearrangements were preferentially targeted to ECDs and the small subset of large LOCK domains, whereas other LOCKs were strongly depleted (Supplementary Fig. 9 ).
Thus, reprogrammed chromatin domains collectively specified malignant gene expression programs, divergent phenotypic properties, and patterns of genome instability that emerged during subclonal evolution in patient A38. We note that a SMARCA2 point mutation of unclear significance was present in A38Lg (C.A.I.-D., unpublished observation), raising the possibility that some epigenetic and/or phenotypic changes could have occurred downstream of this mutation. Although the nature and extent of such findings will certainly vary among patients, they imply that PDAC might be capable of acquiring substantial epigenetic and malignant diversity during subclonal evolution, even in the same cancer from the same patient.
Anabolic glucose metabolism controls epigenetic state and tumorigenicity
We next asked whether a metastasis-intrinsic pathway might have been recurrently selected for during subclonal evolution to exert upstream control over global epigenetic state and tumorigenic potential. Several recent studies have linked metabolism to global levels of histone modifications [24] [25] [26] [27] [28] [29] . Because PDAC distant metastases are largely tropic for organs (liver and lung 2, 3 ) that receive a blood supply that is potentially rich in glucose, we asked whether these subclones might have evolved a dependence on specific aspects of glucose metabolism. Altered glucose metabolism (Warburg effect) is a well-known property of neoplastic and highly proliferative cells 30, 31 . Although most of our metastatic subclones displayed modest proliferative rates in culture (for example, see Supplementary Fig. 2) and in vivo 1 , we nonetheless asked whether distant metastases might have acquired further adaptations in glucose metabolism. Surprisingly, relative to immortalized pancreatic ductal epithelial (HPDE) cells and regional PDAC samples, glucose strongly stimulated metabolic (oxidoreductase) activity across distant metastatic subclones (Fig. 4a) , and glucose was accordingly required for these subclones to withstand oxidative stress (Fig 4b,c) . Distant metastases also hyperconsumed glucose, as we detected elevated glucose uptake and lactate secretion in distant metastases and their precursors (Supplementary Fig. 10a ). To determine whether excess glucose uptake was specifically incorporated into downstream metabolic pathways, we selected matched peritoneal and distant metastatic subclones from the same patient, incubated them with [1,2-13 C]glucose, and measured glucose incorporation into metabolic products with liquid chromatography followed by high-resolution mass spectrometry (LC-HRMS). These experiments revealed elevated incorporation of both [1-13 C]glucose and [1,2-13 C]glucose into lactate and nucleotides in the distant metastasis (Fig. 4d,e) , consistent with enhanced glucose entry into both glycolysis and the PPP.
We next asked whether distant metastases might have evolved a dependence on specific enzymatic steps in either of these glucose-driven pathways, which we hypothesized would manifest as severe depletion of metabolite substrate secondary to hyperconsumption. To test this, we surveyed glycolytic and PPP metabolite profiles across a diverse panel of samples including HPDE cells, peritoneal and distant metastases, and primary tumor precursors. Analysis of all detected glycolytic and pentose phosphate metabolites (Supplementary Fig. 10b ) identified a recurrent depletion of 6-phosphogluconic acid (6PG) across distant metastases and their precursors (Fig. 4f) . 6PG is the substrate for 6-phosphogluconate dehydrogenase (PGD), an enzyme involved in anabolic glucose metabolism that operates within the oxPPP.
Glucose may enter the PPP via the oxPPP or the non-oxidative (noxPPP) branch of the pathway, which are thought to be uncoupled 22 . Although some studies have suggested that PGD is an important oncogene 32 , it is KRAS-mediated noxPPP activation that drives Glucose that enters the oxPPP has one labeled carbon cleaved during conversion of 6PG to Ru5P (m+1), whereas glucose that travels through glycolysis retains both labeled carbons (m+2). Note that crosstalk allows glucose with either labeling pattern to reenter the other pathway and incorporate.
(e) LC-HRMS results for nucleotides and lactate show that these downstream metabolites acquire greatly elevated 13 C labeling from glucose in A38Lg. n = 3 biological replicates; error bars, s.d. *P < 0.01, two-tailed t test. (f) Steady-state LC-HRMS measurements for 6PG show either complete (ND, not detected) or nearly complete loss of this metabolite across distant metastases and their precursors n = 3 biological replicates; error bars, s.d.
primary tumor growth in mouse models of PDAC 22 . Because KRAS and other driver mutations are acquired early in PDAC progression and shared by all subclones that evolve thereafter 1 , we hypothesized that PGD dependence might have been selected for during the evolution of distant metastasis. Glucose deprivation, RNA interference (RNAi) against PGD, and treatment with 6-aminonicotinamide (6AN; a nicotinamide antimetabolite 33 pro-drug reported to preferentially inhibit PGD 34 ) had no effect on global chromatin modifications in the A38 peritoneal subclone, whereas all treatments reversed the reprogrammed chromatin state of the distant metastasis from the same patient (Fig. 5a) . PGD loss of function appeared specific, as PGD knockdown did not alter expression of KRAS or other PPP components (Fig. 5b) .
We next asked whether PGD knockdown might affect intrinsic tumor-forming capacity across a larger panel of subclones. Despite their aggressive behavior in patients, distant metastatic subclones were unable to effectively form metastatic tumors in immunodeficient mice, and PGD RNAi was not toxic in routine 2D cultures (data not shown). To bypass these limitations, we treated cells with PGD RNAi and used 3D Matrigel tumor-forming assays 35 to measure the effects of PGD knockdown on intrinsic tumor-forming capacity. PGD RNAi had minimal effects on the ability of HPDE cells to form spheres or the ability of regional PDACs to form tumors (Fig. 5c) . In contrast, PGD RNAi universally interfered with the ability of distant metastatic subclones to form tumors (Fig. 5d) . These findings suggest that PGD might represent a therapeutic target with selectivity for distant metastases. Because 6AN could represent a lead compound for targeted therapies, we stringently tested it for activity against distant metastases.
6AN treatments slowed rates of glucose consumption and lactate secretion with no effect on glutamine consumption or glutamate secretion in distant metastatic and precursor subclones ( Supplementary  Fig. 11a) , and 6AN reversed the previously detected high incorporation of glucose into lactate and nucleotides (Supplementary Fig. 11b) . Furthermore, steady-state levels of glucose and metabolites directly upstream of the PGD reaction were dramatically elevated in response to 6AN treatment with corresponding reductions in downstream metabolites (Supplementary Fig. 11c ), consistent with strong PGD inhibition 34 .
We next examined our RNA-seq data sets to explore whether the above metabolic changes might be coupled to malignant gene expression programs (Supplementary Table 7h,i) . Remarkably, over half (1,032/1,968; 52%; P < 2.2 × 10 −16 , χ 2 test) of 6AN-downregulated genes from A38Lg corresponded to genes that were overexpressed in this subclone (as compared to A38Per). A large fraction of 6AN-upregulated genes also matched differentially expressed genes that were repressed (915/2,192; 42%; P < 2.2 × 10 −16 , χ 2 test). Even more striking, nearly one-third (255/891; 29%; P < 2.2 × 10 −16 , χ 2 test) of recurrently overexpressed genes across distant metastatic subclones were downregulated by 6AN treatment. The magnitude of the expression changes mediated by 6AN treatment was partial when compared to A38Per transcript levels, as reflected by modest correlation coefficients (r = 0.38; Supplementary Fig. 11d ). This suggested that 6AN might quantitatively target key differentially expressed genes important to maintain malignancy, rather than reversing differentiation state. Indeed, GO analyses indicated that 6AN specifically targeted recurrently overexpressed genes with malignant functions, including those involved in mitotic cell cycle progression, protein acetylation, chromosome stability, DNA repair, and biosynthetic capacity (Supplementary Tables 12-14) .
The gene expression changes prompted us to test the effects of 6AN on epigenetic state. 6AN treatment quantitatively reversed several reprogrammed chromatin modifications across distant metastatic subclones, with minimal effect on normal cells or regional PDACs (Supplementary Fig. 12a,b; summarized in Fig. 6a,b) , and this effect persisted upon removal of 6AN from the medium (Supplementary Fig. 12c ). Because these changes mirrored aspects of LOCK reprogramming, we examined the chromatin state of differentially expressed LOCK genes regulated by 6AN. This analysis revealed that these genes were located within the reprogrammed hybrid LOCK-EI regions (Supplementary Fig. 13a ). ChIP-seq experiments on control and 6AN-treated A38Lg cells further showed that the quantitative increase in global H3K9me2 was targeted to LOCK regions that were reprogrammed in A38Lg versus A38Per (Supplementary Fig. 13b ), while reduced H3K27ac was specifically targeted to genes repressed from LOCKs (Supplementary Fig. 13c ). Similar to the gene expression results, this also reflected a partial 
A r t i c l e s
(quantitative) reversal (r = 0.49; Supplementary Fig. 13d) . Levels of H3K27me3 remained stable across all regions in response to 6AN (Supplementary Fig. 13b-e) , as in the immunoblot findings. Collectively, these experiments demonstrated that 6AN selectively and quantitatively targeted chromatin changes that emerge during the evolution of distant metastasis.
Because 6AN appeared to regulate malignant epigenetic programs, we hypothesized that it might also selectively interfere with the tumorigenic capabilities of distant metastatic subclones. Strikingly, 6AN treatment selectively and strongly blocked tumor formation by distant metastatic and primary tumor precursor subclones but not regional PDACs across multiple 3D experimental platforms, including suspension tumorsphere assays 36 (Supplementary Fig. 14) , Matrigel tumor-forming assays 35 (Fig. 6c) , and injection of PDAC cells into organotypic stroma that recapitulates aspects of in vivo tumorigenesis in patients 37, 38 (Fig. 6d) . Thus, like PGD knockdown, chemical inhibition of PGD by 6AN selectively blocked the tumorigenic potential of distant metastases.
The above findings suggested that tumorigenicity might be mediated in part through metabolic-epigenetic control of malignant gene expression. To more directly test this possibility, we selected two candidate cancer-related genes (Supplementary Note) that were recurrently overexpressed and selectively downregulated by 6AN: CDH2 (N-cadherin) and TOP2B (topoisomerase 2β). ChIP-qPCR performed on 6AN-treated and control cells from matched peritoneal and distant metastatic subclones from the same patient showed minimal changes in H3K9me2 and H3K27ac across these gene loci in the peritoneal (siCDH2) and TOP2B (siTOP2B) (supplementary Fig. 15c,d ) selectively blocks 3D tumor formation in distant metastatic and precursor subclones that overexpress these genes by RNA-seq, with no effect on A38Per or HPDE cells. n = 4 technical replicates; error bars, s.d. *P < 0.01, two-tailed t test. Scale bars, 400 µm.
subclone ( Fig. 7a and Supplementary Fig. 15a ). In contrast, 6AN treatment induced broad enrichment of H3K9me2 across both loci in the distant metastasis, with concordant reductions in H3K27ac over the CDH2 gene itself ( Fig. 7b and Supplementary Fig. 15b ). Loss of expression of these genes was important functionally: knockdown of CDH2 or TOP2B with RNAi partially blocked 3D tumor formation in subclones that overexpressed these genes, with minimal effects on HPDE cells or the peritoneal subclone (Fig. 7c) . These findings further supported the hypothesis that tumorigenic capacity is selectively maintained through metabolic-epigenetic control of malignant gene expression programs.
DISCUSSION
The first major finding of this study was detection of widespread epigenetic reprogramming during the evolution of distant metastasis in the absence of metastasis-specific driver mutations. This manifested as global reprogramming of histone H3K9 and DNA methylation within large heterochromatin domains (LOCKs) as well as regional changes in gene regulatory modifications. Second, these changes specified several divergent malignant properties that emerged during subclonal evolution. Third, it was the PGD step of the oxPPP that controlled reprogrammed chromatin and tumorigenicity in distant metastatic subclones. Collectively, these results suggest that a nongenetic form of natural selection may have emerged during the evolution of PDAC progression and raise several important mechanistic questions for further study (Supplementary Note).
Our findings, in conjunction with deep sequencing studies on many of the same samples reported here 1, 11 , suggest a model whereby driver mutations arise early to initiate PDAC tumorigenesis, followed by a period of subclonal evolution that generates heterogeneous metabolic, epigenetic, and malignant properties. Like driver mutations, those properties that confer increased fitness to cells that acquire them may be selected for and clonally expanded during invasive tumor growth and metastatic spread. The strong oxPPP dependence we observe in distant metastatic subclones could reflect such selection: distant metastatic sites provide ample glucose to fuel the pathway, pathway products enhance biosynthesis and reduce reactive oxygen species, and the pathway itself is coupled to epigenetic programs that promote tumorigenesis. As such, reversal of malignant epigenetic programs by targeting the oxPPP could represent an effective therapeutic strategy for metastatic PDAC, one of the most lethal of all human malignancies.
URLs. Gene annotation information was downloaded from Ensembl (release 66) at http://www.ensembl.org/. Genic sequencing read counts were estimated using HTSeq available from http://www-huber. embl.de/users/anders/HTSeq/doc/overview.html. GO analyses were performed using DAVID functional annotation software available from https://david.ncifcrf.gov/summary.jsp.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. instrument. Briefly, samples were checked for quality and concentration from 150-250 bp on a Bioanalyzer. DNA was end repaired using Klenow polymerase in 58 µl of reaction buffer. For immunoprecipitated DNA, the Klenow polymerase was diluted 1:5. Samples were incubated at 20 °C for 30 min and subsequently purified on QIAquick PCR purification columns. Poly(A) tails were added to the DNA with Klenow polymerase and dATP in NEB Buffer 2 at 37 °C for 30 min, and samples were cleaned with Qiagen MinElute PCR purification columns. Sequencing adaptors were then ligated to the DNA for 15 min at room temperature, followed by cleaning with MinElute columns. Samples were run on 2% agarose gels, and DNA fragments of 216-366 bp in size (DNA plus adaptors) were cut from the gel and purified with Qiagen Gel Extraction kits. DNA concentration was checked on a Bioanalyzer, and 8 ng was PCR amplified with Phusion polymerase (Fisher) for 15 cycles (10 s at 98 °C, 30 s at 65 °C, 30 s at 72 °C) followed by incubation for 5 min at 72 °C. Samples were then cleaned with AMPure kits (Illumina) and washed with 80% ethanol. DNA samples were resuspended at the end of the cleanup into 17.5 µl of EB Buffer (Qiagen) and subjected to next-generation sequencing on the Illumina HiSeq platform according to the manufacturer's instructions. For SOLiD sequencing, ChIP DNA was prepared and samples were processed according to the manufacturer's protocols in the Johns Hopkins CRBII core facility.
WGBS data processing. 100-bp paired-end HiSeq 2000 sequencing reads were aligned using the BSmooth bisulfite alignment pipeline (version 0.7.110) as previously described in detail 6, 40 . Briefly, reads were aligned by Bowtie2 (version 2.0.1) to the human genome (hg19) as well as the lambda phage genome. After alignment, methylation measurements for each CpG site were extracted from the aligned reads. We filtered out measurements with mapping quality <20 or nucleotide base quality at the cytosine position <10, and we also removed measurements from the 5′-most 10 nt of both paired reads. The bsseq package in BSmooth was used to identify small and large differentially methylated regions (DMRs). Only CpGs with coverage of at least 3 reads in all samples were included in our analysis. For small DMRs, a smooth window of 20 CpGs or 1 kb was used, and t-statistic cutoff of -4.6, 4.6 and methylation difference greater than 20% were used for identifying small DMRs. For large DMRs, a smooth window of 200 CpGs or 10,000 bp was used, and t-statistic cutoff of -2, 2, methylation difference greater than 10%, and length of DMRs >5 kb were used for identifying large DMRs.
RNA-seq data processing. 100-bp paired-end HiSeq 2000 sequencing reads were aligned to the human genome (hg19) by OSA (version 2.0.112) with default parameters 41 . After alignment, only uniquely aligned reads were kept for further analysis. Gene annotation information was downloaded from Ensembl (release 66). Read counts for each gene in all samples were estimated using HTSeq and were used to identify differentially expressed genes using the DESeq package 42 . Genes with false discovery rate (FDR) <0.01 and fold change >1.5 were considered to be differentially expressed genes.
ChIP-seq data processing. For 46-bp paired-end Illumina HiSeq 2000 sequencing data, reads were aligned to the human genome (hg19) using BWA with default parameters 43 . After alignment, duplicate reads were removed and only uniquely aligned reads were kept for further analysis. For 48-bp singleend SOLiD sequencing data, reads were aligned using Bowtie 44 with default parameters and only uniquely aligned reads were kept for further analysis. Sequencing reads for immunoprecipitated samples were normalized to those for the corresponding input, and all input libraries were checked to ensure that no sequencing reads from contaminating mycoplasma were detected. For narrow histone modification peaks (H3K4me3 and H3K27ac), MACS2 was used for peak calling with default parameters 45 . For broad histone modification enrichments (H3K36me3, H3K27me3, H3K9me2, and H3K9me3), peak calling was performed using RSEG, which is based on the hidden Markov model (HMM) and specifically designed to identify broad histone peaks 46 .
Identifying large chromatin domains. We defined LOCK domains of heterochromatin modifications (H3K9me2 and H3K27me3) on the basis of the peak calling results from RSEG. Briefly, we first removed peaks of less than 5 kb in length to prevent regions with many nearby short peaks being called as LOCKs. Then, neighboring peaks separated by less than 20 kb were merged into one domain. Merged regions greater than 100 kb in length identified in both biological replicates were called LOCKs. We noticed another unique subset of heterochromatin domains (large LOCKs) that were invariably longer than 500 kb in length, strongly enriched with H3K9me3, depleted of H3K9me2 and H3K27me3, and flanked by strong peaks of H3K27me3 at the boundaries. On the basis of these findings, we defined these LOCKs as having H3K9me3 regions of greater than 500 kb in length with less than 50% of their length overlapped by H3K27me3 peaks. Finally, the large regions (>50 kb in length) between heterochromatin domains that contained at least one gene with corresponding euchromatic H3K4me3 and H3K27ac regulatory peaks were defined as ECDs. Because we found that H3K27ac alone was sufficient for these calls, H3K4me3 was also used for the initial test data set with A38Per and A38Lg but was not required in subsequent data sets (A13Pr1, A13Pr2, and A13Lg).
Defining different gene groups. Genes were classified as being located in euchromatin (where >50% of the genic region was located in ECDs) or heterochromatin (where >50% of the genic region was located in heterochromatin domains). A handful of other genes that did not meet these criteria were classified as 'other' .
Quantification and enrichment plotting for ChIP-seq and RNA-seq data. To plot each histone modification on defined large chromatin domains and their flanking regions, we divided the flanking sequences of chromatin domains into bins of fixed length (in base pairs) and domains themselves into bins of a fixed percentage of each domain length. ChIP enrichment was measured and normalized as described previously 47 . In brief, the number of reads per kilobase of bin per million reads sequenced (RPKM) was calculated for each ChIP and its input control (denoted as RPKM ChIP and RPKM input ). ChIP enrichment was measured as ∆RPKM = RPKM ChIP -RPKM input , and ChIP enrichment regions should have ∆RPKM >0. All ∆RPKM values were normalized to a scale from 0 and 1, and the average normalized ChIP enrichment signals across all large chromatin domains were plotted for each histone mark. RNA-seq data were also normalized by RPKM and were plotted similarly.
Statistical tests of significance. Tests for statistical significance (two-tailed Student's t test) were performed on data collected from technical replicates (performed in parallel at the same time) or biological replicates (performed at different times) as indicated in the figure legends, using Microsoft Excel software for immunoblot densitometry, MTT assays, and tumor measurements. Permutation tests for overlapping genomic intervals were performed in R software using GenometriCorr 48 . For comparisons between groups, χ 2 and Wilcoxon rank-sum tests were performed using R software (version 3.3.1).
Data availability. All ChIP-seq, WGBS, and RNA-seq data sets are available from the Gene Expression Omnibus (GEO) under accession GSE63126.
